CD19 and congenital rubella syndrome: In agreement with the previous studies (42), we did not observe any association between PET/CT parameters and CRS, possibly because of the relatively limited number of patients included and the small number of high-grade CRS (≥2) in patients receiving CD19/CD22 CAR T-cell therapies.